20180006
#25074058.0

Mild Cognitive Impairment & Alzheimer's Disease

Patients with mild cognitive impairment (MCI) experience changes in their memory for recent events that is greater than would be expected for their age.

Usually these changes are not severe enough to interfere with day-to-day activities.

Unfortunately, a person with amnestic MCI (aMCI) is at an increased risk of developing Alzheimer's or another dementia.

By age 85, one of every three people will have Alzheimer's disease. Today 5.6 million Americans suffer from MCI due to AD, and this number will double by 2030.

If you are worried about your memory or the memory of a loved one, your healthcare provider might decide to refer you to a specialist such as a neurologist or a neuropsychiatrist for an evaluation.

About Clinical Trials

A clinical trial is a research study with the goal of answering specific questions about how to better treat a disease. Clinical trials are used to determine whether new drugs are both safe and effective. Carefully conducted clinical trials are the fastest and safest way to find treatments that work in people.

Contact Us

Please contact us at any time to learn more about participating in the HOPE4MCI trial!

The NeuroCognitive Institute
111 Howard Blvd, Suite 204-205
Mount Arlington, NJ 07856

Phone: **973 601 0100**
Email: **amarmeto@neuroci.com**
Website: hope4mci.org

HOPE4MCI

IRB Conditions Satisfied at the Protocol Level Aug 07, 2019 Panel 10

Worried about Your Memory?

If you or a loved one are suffering from memory loss, please consider the HOPE4MCI clinical research trial

HOPE4MCI study

The HOPE4MCI Trial is a global Phase 3 clinical research study that will assess the effectiveness and safety of an investigational medication to determine if it can slow the progression of symptoms associated with aMCI and prevent or delay the onset of Alzheimer's dementia.

HOPE4MCI

What happens during the study?

Study volunteers will be assessed for entry into the clinical research study. You will be asked to sign a consent form and give your medical health history and current medicines you may be taking. Additionally, some initial medical and cognitive testing will be preformed to find out if you can be in the study.

Enrolled participants will receive the investigational medication, a once-a-day oral tablet, or a placebo once-a-day oral tablet over a period of 18 months. The investigational medication is an FDA-approved and commonly prescribed medication for epilepsy, but during this research trial, the dose will be considerably lower.

Participants will be assessed medically and by clinical and cognitive rating scales, receive positron emission tomography (PET) scans, and receive a magnetic resonance imaging (MRI) scans.

Who can participate?

- People whose symptoms are consistent with a diagnosis of aMCI
- People who have a positive amyloid PET scan